The Government's Rush To Judgment On Bernard Fisher's Work, Reputation

The Government's Rush To Judgment On Bernard Fisher's Work, Reputation The Scientist, Vol:9, #23, pg.12 , November 27, 1995. Author: Eugene Garfield                       Most readers of The Scientist probably are familiar with the case of Bernard Fisher, the University of Pittsburgh professor who had directed the National Surgical Adjuvant Breast and Bowel Project (NSABP) for more than two decades. Over that time, the 100 or so papers

Written byEugene Garfield
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

But journalist John Crewdson of the Chicago Tribune reported on an Achilles' heel in NSABP. In this massive, multi-institutional, multinational, multimillion-dollar study funded by the National Cancer Institute (NCI), Crewdson wrote in 1994, a Canadian member of the project had enrolled some 100 ineligible patients (J. Crewdson, Chicago Tribune, March 13, 1994, page 1). Although a reanalysis concluded that these records did not affect the project's significance or conclusions, Fisher was removed by NCI as the NSABP director.

According to a recent report by Dan Greenberg in Science and Government Report (25:1-3, Nov. 1, 1995), the government has added insult to injury in the Fisher case. The National Library of Medicine (NLM) has placed "scientific misconduct" tags on the NSABP papers-some of which do not include the Canadian data-apparently under pressure from NCI. Donald Lindberg, NLM's director, acknowledges this as an extraordinary action, saying he knows of no other case ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies